Moderna Flu Shot Outperforms in Global Phase 3 Trial

Moderna's mRNA-1010 seasonal flu vaccine showed 26.6% greater efficacy than a standard-dose licensed flu shot in adults 50 and older, and 27.4% in those over 65, according to a Phase 3 trial involving over 40,000 participants across 11 countries. The vaccine demonstrated consistent efficacy against multiple influenza strains and had a favorable safety profile with mostly mild reactions. Moderna had previously withdrawn its combination flu and COVID-19 vaccine submission to await these efficacy results and now plans to submit for regulatory approval later this year. Success could give Moderna an edge over competitors Pfizer and Novavax in marketing a combination vaccine. The mRNA-based technology allows for closer matching to circulating flu strains, potentially reducing healthcare burdens and costs. Moderna intends to present the study findings at an upcoming medical conference and engage with regulators for approval.